Meta-Analysishigh evidence
Comment on: cardiovascular and prostate cancer risk associated to testosterone replacement therapy-a systematic review and meta-analysis of 41 randomized controlled trials.
International journal of impotence research·June 22, 2026·PMID 42332077
Why it mattersCardiovascular and prostate cancer risks are central safety concerns when prescribing TRT, and clinicians need clear, evidence-based guidance to counsel patients appropriately. This commentary may highlight nuances in the meta-analytic evidence that affect risk–benefit discussions.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled